Abstract: SA-PO0559
Prevalence of Depression, Chronic Pain, and Sleep Disorders in ADPKD in the US Military Health System (MHS)
Session Information
- Cystic Kidney Diseases: Clinical Research
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Genetic Diseases of the Kidneys
- 1201 Genetic Diseases of the Kidneys: Monogenic Kidney Diseases
Authors
- Silverberg, Rachael A., Walter Reed National Military Medical Center, Bethesda, Maryland, United States
- Nee, Robert, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States
- Marneweck, Hava, Henry M Jackson Foundation for the Advancement of Military Medicine Inc, Bethesda, Maryland, United States
- Banaag, Amanda, Henry M Jackson Foundation for the Advancement of Military Medicine Inc, Bethesda, Maryland, United States
- Han, Sola, Centers for Disease Control and Prevention, Atlanta, Georgia, United States
- Pavkov, Meda E., Centers for Disease Control and Prevention, Atlanta, Georgia, United States
- Koehlmoos, Tracey L., Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States
- Oliver, James D., Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States
Background
Mental health and pain have been identified as important factors affecting the quality of life (QoL) of people with PKD. Our goal was to evaluate the prevalence of these conditions in a large PKD population from the MHS, a global US Department of Defense healthcare network.
Methods
For the 2022 enrollment of 5,028,667 beneficiaries, we used ICD-10 diagnosis codes and/or labs from the previous 6 years to identify 3,382 (0.07%) with PKD (PKD+), 264,883 (5.3%) with non-PKD chornic kidney disease (CKD+/PKD–), and 4,760,402 (94.7%) without CKD (CKD–). The outcomes were the prevalence of depression, chronic pain, and sleep disorders as defined by diagnosis codes. Adjusted odds ratios (aOR) were calculated using multivariable logistic regression. Sponsor military rank was used as a surrogate for socioeconomic status.
Results
The crude prevalence of depression was 21.4% in PKD+, 27.6% in CKD+/PKD–, and 11.7% in CKD–. For chronic pain, the respective crude prevalence was 24.8%, 27.6%, and 10.0%; and for sleep disorders it was 42.9%, 46.7%, and 20.7%. The unadjusted odds ratios (uOR) for all three conditions were greater than 2 (p<.05) for PKD+ vs. CKD–, but less than 1 (p<.05) for PKD+ vs. CKD+/PKD– (Table). After adjustment for demographic factors (age, sex, race, ethnicity, active-duty military status, and sponsor rank), the aORs for PKD+ vs CKD– remained significantly higher for all three conditions. For PKD+ vs. CKD+/PKD– the aOR for depression was significantly lower, while there was no difference for chronic pain and sleep disorders.
Conclusion
In the MHS, PKD is associated with increased odds of depression, chronic pain, and sleep disorders vs. the non-CKD population; however, these odds are not increased compared to other forms of CKD. Further investigation is required to evaluate therapeutic strategies to improve QoL in people with PKD.
The views expressed are those of the authors and do not reflect the official position of the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Department of Defense, the Department of Health and Human Services, or the US Government.
Funding
- Other U.S. Government Support